Literature DB >> 7785748

Current practice: diagnosis and treatment in primary healthcare.

D BenEzra1.   

Abstract

In a primary healthcare facility, there are certain 'rules of thumb' that can be recommended for the diagnosis and treatment of conjunctivitis. The type of discharge is a crucial factor in the differential diagnosis and can also be a clue towards the management in primary care. It is important to identify whether the conjunctivitis is an isolated case or part of another disease, and if it is acute or chronic, and I would suggest taking a smear or culture sample whenever possible. When the aetiology is not clear, I would try antibiotics. If the patient is allergic, and an allergic conjunctivitis is suspected, the best management today is to use mast cell stabilisers, and combine these with conservative measures of frequent washings, and compresses. If the aetiology remains doubtful, or if there is no obvious improvement using these treatments, the patient should be re-evaluated and/or referred to an ophthalmologist or specialist eye centre. The use of corticosteroids for conjunctivitis should certainly be avoided in primary healthcare. Conjunctivitis is often self-limited and the drug-induced consequences of improper management can be far more devastating than the disease itself.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7785748     DOI: 10.1111/j.1398-9995.1995.tb04254.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  2 in total

1.  Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety.

Authors:  Veysi Oner; Fatih Mehmet Türkcü; Mehmet Taş; Mehmet Fuat Alakuş; Yalçın Işcan
Journal:  Jpn J Ophthalmol       Date:  2012-05-25       Impact factor: 2.447

Review 2.  Acute infective conjunctivitis in primary care: who needs antibiotics? An individual patient data meta-analysis.

Authors:  Joanna Jefferis; Rafael Perera; Hazel Everitt; Henk van Weert; Remco Rietveld; Paul Glasziou; Peter Rose
Journal:  Br J Gen Pract       Date:  2011-09       Impact factor: 5.386

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.